Clinical Trial

MSC Intratissular Injection in Crohn Disease Patients

Study acronym: MSC
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated December 12, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
The main objective is to assess the efficacy of local injection of MSC on the healing of refractory intestinal and perianal lesions in crohn disease. The second co-primary endpoint is safety.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2019-04-02; most recent amendment 2024-12-06.
Trial Details
NCT Number NCT03901235
Lead Sponsor University of Liege
Collaborators: Centre Hospitalier Universitaire de Liege
Conditions Efficacy and Safety
Enrollment 60 participants
Start Date 2018-01-15
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-12-12